| 5.07 0 (0%) | 08-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.03 | 1-year : | 6.21 |
| Resists | First : | 5.16 | Second : | 5.32 |
| Pivot price | 5.08 |
|||
| Supports | First : | 4.9 | Second : | 4.08 |
| MAs | MA(5) : | 5.07 |
MA(20) : | 5.08 |
| MA(100) : | 5.08  |
MA(250) : | 4.38 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 24.2 | D(3) : | 24.3 |
| RSI | RSI(14): 49.8 | |||
| 52-week | High : | 5.84 | Low : | 2.71 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ XYLO ] has closed above bottom band by 45.3%. Bollinger Bands are 50.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.08 - 5.11 | 5.11 - 5.13 |
| Low: | 5 - 5.03 | 5.03 - 5.06 |
| Close: | 5.02 - 5.07 | 5.07 - 5.12 |
Xylo Technologies Ltd, a technology-based company, provides medical-related devices and products in the United States, Europe, Asia, Israel, and internationally. The company operates through Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and Others segments. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it provides digital advertising platform; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops wireless vehicle battery charging technologies and modular electronic vehicles. The company was formerly known as Medigus Ltd. and changed its name to Xylo Technologies Ltd in April 2024. Xylo Technologies Ltd was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.
Mon, 01 Dec 2025
SciSparc acquires Xylo Technologies' innovative endoscopic portfolio - Indian Pharma Post
Fri, 22 Aug 2025
L.I.A. Pure Capital Ltd. completed the acquisition of remaining 91.13% stake in Xylo Technologies Ltd. - marketscreener.com
Fri, 22 Aug 2025
Xylo Technologies Completes Acquisition by Pure Capital - TipRanks
Tue, 12 Aug 2025
Xylo Technologies Ltd. to Delist from Nasdaq Following Acquisition - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 9 (%) |
| Held by Institutions | 5.8 (%) |
| Shares Short | 13 (K) |
| Shares Short P.Month | 4 (K) |
| EPS | -8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.29 |
| Profit Margin | -20.2 % |
| Operating Margin | -37.8 % |
| Return on Assets (ttm) | -10.5 % |
| Return on Equity (ttm) | -48 % |
| Qtrly Rev. Growth | -72.5 % |
| Gross Profit (p.s.) | 5.21 |
| Sales Per Share | 23.32 |
| EBITDA (p.s.) | -3.76 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | -0.64 |
| PEG Ratio | 0 |
| Price to Book value | 0.22 |
| Price to Sales | 0.21 |
| Price to Cash Flow | -3.57 |
| Dividend | 2.26 |
| Forward Dividend | 0 |
| Dividend Yield | 44.7% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|